N/A
N=32
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
Dyskinesias · Movement Disorders · Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT00467597 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcome: Primary: Gaitmat Stance Measurements (AUC) — 4.48; 10.8; 20.9; 2.8 Root Mean Square of Velocity*Minutes
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Levodopa (delivered intravenously) (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- US Department of Veterans Affairs
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gaitmat Stance Measurements (AUC) |
4.48; 10.8; 20.9; 2.8 | — |
Summary
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of probable idiopathic Parkinson's Disease or no neurologic disease (no disease for controls only)
- At least 21 years of age
- Mini Mental Status Exam Score>=25
Exclusion Criteria
- Evidence of psychosis (hallucinations or delusions) by history
- Any unstable medical condition
- Currently using dopamine blocking medication
- Currently taking anticoagulants or MAO inhibitors
Data sourced from ClinicalTrials.gov (NCT00467597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.